Bellicum Pharmaceuticals, Inc. Sustainability Profile
Bellicum Pharmaceuticals, Inc., a pioneering biopharmaceutical company headquartered in the United States, focuses on developing innovative cell therapies for cancer and other life-threatening diseases. Founded in 2004, Bellicum has made significant strides in the field of immunotherapy, particularly with its proprietary GoCAR-T™ technology, which enhances the efficacy and safety of CAR T-cell therapies. With a strong presence in the oncology sector, Bellicum is dedicated to advancing its core products, including BPX-601 and BPX-701, which are designed to target specific cancer antigens. The company has garnered attention for its unique approach to cell therapy, positioning itself as a leader in the rapidly evolving landscape of cancer treatment. Bellicum's commitment to innovation and patient-centric solutions underscores its notable achievements in the biopharmaceutical industry.
DitchCarbon Score
How does Bellicum Pharmaceuticals, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Bellicum Pharmaceuticals, Inc.'s score of 23 is lower than 73% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Bellicum Pharmaceuticals, Inc.'s reported carbon emissions
Bellicum Pharmaceuticals, Inc., headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. This lack of emissions data and climate commitments suggests that Bellicum Pharmaceuticals may not have established formal initiatives to address its carbon footprint or align with industry standards for sustainability. As the pharmaceutical industry increasingly prioritises climate action, it remains essential for companies like Bellicum to develop and communicate their environmental strategies to enhance transparency and accountability in their operations.
How Carbon Intensive is Bellicum Pharmaceuticals, Inc.'s Industry?
How Carbon Intensive is Bellicum Pharmaceuticals, Inc.'s Location?
Bellicum Pharmaceuticals, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Bellicum Pharmaceuticals, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
